Roche Holdings has launched a new platform for personalized cancer treatment, which uses artificial intelligence (AI) to tailor treatment plans to individual patients.
The Role of AI in Cancer Treatment
The platform, known as FoundationOne, uses machine learning algorithms to analyze genomic data and identify the most effective treatment options for each patient. The platform has been shown to increase treatment efficacy by 25% in clinical trials.
The platform has been used to treat over 10,000 patients with cancer, with a significant improvement in patient outcomes.
Our new platform has the potential to revolutionize cancer treatment, and we are committed to making it available to patients around the world, said Severin Schwan, CEO of Roche Holdings.